Transcenta Holding
Latest round
- Series B
Last raised
- Dec 2020
Total raised
- $205M
Investors
- 15
About Transcenta Holding
Established in 2019 and based in Suzhou, China, Transcenta Holding Ltd. operates as a biopharmaceutical company that focuses on research, development, and manufacturing of biologics., a biotechnology company that focuses on the development of antibody-based therapeutics for the treatment of cancer and fibrotic disorders affecting the lungs, kidneys, and liver. The company has product development center and production base in Hangzhou, and clinical development centers in Shanghai, Beijing and Boston, USA. The company has develops nine new drug molecules, covering oncology, orthopedics and kidney disease. It focuses on reduce the time from drug target to BLA and to apply high quality next-generation GMPs. The company established partnerships with Libang Pharmaceutical and other biotechnology companies using his clinical expertise in nephropathy to co-develop TST004 in China.
Who invested in Transcenta Holding
15 investors across 2 rounds
See all investors in Transcenta Holding
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Transcenta Holding
Who invested in Transcenta Holding?
Transcenta Holding has 15 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Transcenta Holding raised?
Transcenta Holding has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Transcenta Holding last raise money?
Transcenta Holding's most recent round on record is a Series B, in Dec 2020.
What does Transcenta Holding do?
Established in 2019 and based in Suzhou, China, Transcenta Holding Ltd.
Where is Transcenta Holding headquartered?
Transcenta Holding is headquartered in Suzhou, China.
Which VCs invest in companies like Transcenta Holding?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Transcenta Holding's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Transcenta Holding? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.